Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Eyetech Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Diabetic Macular Edema

Treatments: Drug: pegaptanib sodium (Macugen)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00040313

EOP1005

Details and patient eligibility

About

The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients with clinically significant DME, VA 20/50-20/320 in the study eye and 20/100 in the fellow eye

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind